GLP-1s and 'food noise': what the science says about appetite signaling

What did @bianca.hwb actually say?

Bianca is on 1 mg semaglutide (Ozempic) and comparing her experience to a previous run on tirzepatide. Her core claim: tirzepatide made her food noise "just go poof" while semaglutide at 1 mg has reduced it but not eliminated it. She's also hesitant to go up to 2 mg because a friend "got so so sick" at that dose. She frames all of this as personal experience, not medical advice, which matters.

This is genuinely useful first-person reporting. She's not telling anyone what to do. She's describing a real pharmacological difference between two drugs that clinical data actually supports, even if she doesn't know the mechanism behind it.

Does the science back this up?

Yes, more than you might expect from a TikTok video. The difference in appetite suppression between semaglutide and tirzepatide is real and documented. Tirzepatide acts on both GLP-1 and GIP receptors, while semaglutide is a GLP-1 agonist only. That dual mechanism appears to produce stronger appetite suppression in a meaningful portion of patients.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide produced up to 20.9% mean body weight reduction at the highest dose. The STEP 1 trial for semaglutide (Wilding et al., 2021, NEJM) showed roughly 14.9% mean weight loss. These aren't just weight numbers, they reflect real differences in how strongly each drug suppresses appetite-related signaling. Bianca's lived experience tracks with what the trial data suggests: tirzepatide tends to hit harder on appetite, at least for many users.

On the side effect concern at higher doses: nausea and gastrointestinal distress are dose-dependent with semaglutide. Davies et al. (2021, Diabetes Care) confirmed that adverse GI events increase as doses escalate, which is exactly what her friend experienced at 2 mg.

What did they get wrong (or right)?

Bianca got the core comparison right intuitively, even without knowing the pharmacology. Tirzepatide's dual-agonist mechanism likely explains why her food noise felt more completely silenced on that drug. That's not placebo or coincidence, it's a plausible pharmacological difference.

What she got slightly wrong is the framing around the Ozempic dose. The standard approved maintenance doses for Ozempic in type 2 diabetes are 0.5 mg and 1 mg weekly. A "2 mg" dose does exist (approved in 2023 for type 2 diabetes), but its use is specific and not universally appropriate. She presents the 1-to-2 mg conversation as a simple preference choice, when it's actually a clinical decision that depends on HbA1c, weight loss goals, tolerability, and the prescriber's judgment. That framing isn't dangerous here since she says she has a follow-up with her doctor, but it could mislead viewers into thinking dose escalation is just a personal vibe call.

She also calls the medication "ozampic" throughout, which is a pronunciation issue, not a factual error. Minor, but worth noting for credibility.

What should you actually know?

The food noise difference between GLP-1 only drugs and dual GLP-1/GIP agonists is one of the more clinically interesting open questions right now. It's not fully understood why some people experience dramatic appetite suppression on one and not the other, and individual response varies substantially. Researchers are actively studying whether GIP receptor activity specifically modulates reward-related eating behavior, separate from caloric regulation.

If you're on semaglutide and not getting the appetite suppression you expected, that's worth a real conversation with your prescriber, not a TikTok comment section diagnosis. The answer might be a dose adjustment, a switch in medication, or a closer look at other factors like sleep, stress, or PCOS-related insulin resistance, which Bianca hashtags suggest may be relevant to her case.

Dose escalation decisions should be driven by clinical outcomes and tolerability, not by fear of a friend's experience or impatience with partial results. Both are understandable human reactions, but neither is a clinical framework.

The PCOS angle she didn't mention

Bianca tags PCOS but doesn't discuss it in the video. That omission is worth flagging because PCOS significantly affects how people respond to GLP-1 drugs. Insulin resistance, which is common in PCOS, can affect both the metabolic response to semaglutide and the degree of appetite modulation experienced. Cree et al. (2021, Journal of Clinical Endocrinology and Metabolism) found that GLP-1 receptor agonists showed particular benefit in women with PCOS and obesity. If her prescriber isn't factoring PCOS into the dose conversation, that's a missed clinical opportunity.